20 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Apr 2028
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2037 · High confidence
Also notable
Ends Sep 2035 · High confidence
Also notable
Ends Apr 2041 · High confidence
Psilocybin Compositions
US 11,590,120
Cited by 44 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Antiviral Activity from Medicinal Mushrooms and their Active Constituents
US 9,931,316
The most cited patent in this portfolio, cited by 57 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2035.
Compositions and Methods for Modulating Inflammatory Response
US 11,730,784
Cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Tryptamine Compositions for Enhancing Neurite Outgrowth (US 11,660,305) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 18, 2027The maintenance fee for Psilocybin Compositions (US 11,701,348) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Compositions and Methods for Modulating Inflammatory Response (US 11,730,784) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for Method for Monitoring Bee Visits to a Bee Feeder Having Labyrinthine Passages (US 11,758,886) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for Combined Fungal Composition for Modulating Inflammatory Response (US 11,779,620) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Tryptamine Compositions for Enhancing Neurite Outgrowth (US 11,850,254) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Tryptamine Compositions for Enhancing Neurite Outgrowth (US 11,896,587) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Psilocybin Compositions | 10 in force | to Sep 2037 |
| Combined Fungal Composition for Modulating Inflammatory Response | 4 in force | to Apr 2041 |
| Bee Feeder Having Labyrinthine Passages | 4 in force | to Jan 2040 |
| Antiviral and Antibacterial Activity from Medicinal Mushrooms | 2 in force | to Sep 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,765,138 | Antiviral and Antibacterial Activity from Medicinal Mushrooms In force · Low confidence | In force | Low confidence | |
| US 9,931,316 | Antiviral Activity from Medicinal Mushrooms and their Active Constituents In force · High confidence | In force | High confidence | |
| US 11,590,120 | Psilocybin Compositions In force · High confidence | In force | High confidence | |
| US 11,701,348 | Psilocybin Compositions In force · High confidence | In force | High confidence | |
| US 11,896,587 | Tryptamine Compositions for Enhancing Neurite Outgrowth In force · High confidence | In force | High confidence | |
| US 12,171,771 | Tryptamine Compositions for Enhancing Neurite Outgrowth In force · High confidence | In force | High confidence | |
| US 12,257,258 | Tryptamine Compositions for Enhancing Neurite Outgrowth In force · High confidence | In force | High confidence | |
| US 12,403,150 | Tryptamine Compositions for Enhancing Neurite Outgrowth In force · High confidence | In force | High confidence | |
| US 12,766,156 | Tryptamine Compositions for Enhancing Neurite Outgrowth In force · High confidence | In force | High confidence | |
| US 11,471,450 | Psilocybin Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 10 patents ended · 6 applications pending · 33 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.